<DOC>
	<DOCNO>NCT00462878</DOCNO>
	<brief_summary>Observational study compare treatment neutropenic patient allogenic blood stem cell transplantation , meropenem meropenem plus glycopeptide .</brief_summary>
	<brief_title>Meropenem Versus Meropenem Plus Glycopeptide Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation</brief_title>
	<detailed_description>Observational study cost-effectivity compare treatment neutropenic patient allogenic blood stem cell transplantation , meropenem meropenem plus glycopeptide . The study do two consecutive cohort patient . First cohort : meropenem 1g/8h ev Second cohort : meropenem 1g/8h glycopeptide ( vancomycin 1g/12 h teicoplanin 400 mg/24h )</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>Age &gt; 18 year Patients submit allogenic transplant Neutropenia : neutrophils account &lt; 500/mm3 neutrophil account &lt; 1000/mm3 prevision decrease 500/mm3 next 2448 h Signs symptom infection Fever : Temperature &gt; 38,3 ºC register one time , 38 ºC en two time separate 60 minute period 12 h. Medical history meropenem glycopeptides hypersensitivity Renal failure creatinine serum &gt; 2,25 mg/dl creatinine clearance &lt; 40 ml Liver insufficiency Childbearing potential breast feeding period Contraindications meropenem , vancomycin teicoplanin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Febrile neutropenia</keyword>
</DOC>